GLP-1 drugs like semaglutide (Ozempic, Wegovy) showed promise in preclinical studies for Alzheimer’s disease (AD) due to neuroprotective effects. Recent large-scale clinical trials have found they do not slow disease progression or improve cognition in early AD, disappointing initial hopes. Researchers remain cautiously optimistic about potential future uses, possibly in combination treatments or different formulations, but current data suggest metabolic improvements alone aren’t enough to stop cognitive decline.
Addressing the dysfunctions of all brain cell types in Alzheimer’s disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, astroglia, microglia, endothelial cells, and pericytes. This article describes the benefits provided to all of those brain cell types by GLP-1 agonist drugs. The article uses studies in humans, not rodents, to describe the effect of GLP-1 agonists upon cognition, because rodents’ brains differ from those of humans in so many ways that results from rodent studies may not be totally transferable to humans.
Commercially available GLP-1 agonists have mostly shown either positive effects on cognition or no effects. One important reason for no effects is a reduced rate of entering the brain parenchyma. Dulaglutide has the greatest entry to the brain, at 61.8%, among the available GLP-1 agonists, and seems to offer the best likelihood for the cure of AD. Although there is only one study of cognition that used dulaglutide, it was randomized, placebo-controlled, and very large; it involved 8828 participants and showed a significant benefit to cognition. A clinical trial to test the hypothesis that dulaglutide may cure AD should have, as its primary outcome, a 30% greater cure rate of AD by dulaglutide than that achieved by an equipoise arm of, e.g., lithium plus memantine.
GLP-1 agonists, Alzheimer’s dementia, cure, brain cells
Cure should be the goal of therapy for Alzheimer’s dementia (AD). One approach is to address all of its major causal factors, but that requires the administration of an unfeasible number of drugs. Since the ultimate, underlying cause of the dementia is dysfunction of brain cells, addressing all of those dysfunctions is another approach to curing it; using that approach, GLP-1 agonists may cure the dementia because, as shown below, all of the major, dysfunctional brain cell types in AD, including neurons, oligodendroglia, astrocytes, microglia, endothelial cells, and pericytes, express receptors for the glucagon-like peptide 1.
The account by Holst provides a brief introduction to the 30-amino acid peptide hormone, glucagon-like peptide 1 . GLP-1 is a product of the glucagon gene. The primary translation product, proglucagon, a peptide of 160 amino acids, contains, apart from the glucagon sequence, two glucagon-like sequences designated GLP-1 and GLP-2. They are glucagon-like because, with respect to amino acid sequence, they are about 50% homologous to glucagon. When the prohormone is processed, the glucagon sequence is cleaved out, whereas the part containing the GLPs is secreted as a single, large peptide”.
GLP-1 and Brain Cells
GLP-1 agonists have been extensively studied in relation to their effect on energy metabolism and nutrition. In that respect, and a link with GLP-1, a risk factor for developing AD is being underweight, a condition that is countered by GLP-1 agonists. In fact, the nutritional status of AD patients is significantly compromised and tends to worsen with the progression of AD. Further links between a GLP-1 agonist and AD are the facts that a disturbed circadian rhythm occurs in AD, that blood levels of circadian clock proteins are increased in sleep apnea [6], and that the GLP-1 agonist, tirzepatide, benefits sleep apnea. GLP-1 receptors exist in various brain regions, including the nucleus accumbens and the brainstem. GLP-1-activated paraventricular signaling mounts a whole-organism response to stress. Data in the following sections show GLP-1 receptors in all brain cell types.
GLP-1 and Neurons
GLP-1 is widely present in the brain, where it is neuroprotective by reducing neuronal apoptosis and by promoting both neurite outgrowth and synaptic plasticity. The neuronal marker c-fos shows neuroanatomical connections, and enabled the demonstration that peripherally administered GLP-1 increased neuronal expression in the brainstem and amygdala. GLP-1 receptors are abundant in the c-brain stem, where preproglucagon neurons in the solitarius nucleus produce GLP-1 and project to many regions, including the hypothalamus. In the arcuate nucleus of the hypothalamus, which contains GLP-1 receptor, the GLP-1 agonist liraglutide caused activation of pro-opiomelanocortin neurons and inhibition of neuropeptide Y/agouti-related peptide neurons via post-synaptic GABAA receptors, but enhancement of pre-synaptic GABAergic neurons. GLP-1R mRNA expression was also seen in both cultured, embryonic primary cerebral cortical neurons and ventral mesencephalic (dopaminergic) neurons, both of which are vulnerable to hypoxia- and 6-hydroxydopamine-induced cell death, from which GLP-1 conferred protection.
As regards the effect of GLP-1 in AD, it reduced the effects of Aβ and plaque formation in AD model mice, and measures of nutrition, with which GLP-1 is strongly connected, were associated with mortality in patients with AD. That is notable because in a study of 79 patients with AD, 22 died during five years, and being underweight was a major risk factor for that mortality, with a hazard ratio (HR) of 3.34, and poor nutrition had an HR of 5.6.
GLP-1 and Oligodendroglia
Oligodendrocytes, which carry a GLP-1 receptor, have a key role in the myelination of neurons and are decreased in AD. After spinal cord injury, administration of the GLP-1 agonist, exenatide, led to a significant increase in survival of oligodendrocyte progenitor cells, and those pre-oligodendrocytes were decreased in a mouse model of AD.
GLP-1 and Astrocytes
The presence of GLP-1 receptors in astrocytes was demonstrated by Reiner et al., who found that the uptake of a systemically administered fluorophore-tagged GLP-1 agonist exendin-4 was blocked by pretreatment with the competitive GLP-1R antagonist exendin-(9–39). The addition of GLP-1 reduced the declines in glycolysis in astrocytes that had been induced by Aβ, and liraglutide administered to AD patients prevented a decline in glucose metabolism in their brains but did not benefit cognition.
GLP-1 and Microglia
Microglia express receptors for GLP-1, probably accounting for the anti-inflammatory effects of GLP-1 agonists: liraglutide caused significantly decreased levels of IFN-γ, TNF-α, and IL-6; and semaglutide led to reductions in CRP that were positively correlated with reductions in bodyweight, waist circumference, fasting plasma glucose, and fasting serum insulin.
GLP-1, Endothelial Cells, and Pericytes
Endothelial cells (EC) from human coronary arteries expressed the receptor for GLP-1. EECs are among those protected by the inhibition of reactive oxygen species (ROS) that is induced by GLP-1. GLP-1 agonism also induced up-regulation of miR-155 expression in endothelial progenitor cells. The GLP-1 agonist exenatide prevented high-glucose and lipid-induced endothelial dysfunction in cultured human arterioles. Pericytes were also protected by GLP-1 against the toxicity produced by ROS [34]. Pericytes have contractile properties and control the cerebral microvascular flow (CMF). Because the CMF is dysfunctional in AD, its protection by GPL-1 agonists has a potential therapeutic benefit.
If the premise is correct, that addressing all of the affected brain cell types might cure AD or any other neurodegenerative disease, then this article shows that GLP-1 agonists should cure AD, because they address neurons/synapses, oligodendroglia, astroglia, microglia, endothelial cells, and pericytes. However, as a class, GLP-1 agonists fall short of curing AD, so either the premise is incorrect, or there is some other explanation for the failure. It is improbable that the premise is incorrect, since all neurodegenerative diseases result from dysfunction, however generated, of some or all brain cell types [40]. The likeliest explanation comes from data showing that the available GPL-1 agonists have different percentages of either their entry to the brain or in their beneficial effects.
Reference:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11242057/
https://www.medicalnewstoday.com/articles/can-glp-1s-actually-help-treat-alzheimers-latest-trial-data
Medications that have been suggested by doctors worldwide are available on the link below
https://mygenericpharmacy.com/category/disease/alzheimer-disease